Publications by authors named "R M Saliba"
Bacteriology of Aspiration Pneumonia: The Lung Microbiome and the Changing Microbial Etiology.
Semin Respir Crit Care Med
December 2024
Aspiration pneumonia refers to the process of alveolar inflammation induced by the inhalation of oropharyngeal secretions into the lower respiratory tract. Predisposing factors comprise swallowing dysfunction, impaired cough reflex, and degenerative neurological diseases. Accumulating evidence projects a fading contribution of anaerobic bacteria in aspiration pneumonia at the expense of Gram-negative bacilli, with , , and , becoming the predominant organisms recovered from respiratory specimens.
View Article and Find Full Text PDFArticle Synopsis
- Philadelphia-like acute lymphoblastic leukemia (Ph-like ALL) is a high-risk type of B-cell ALL that is difficult to treat effectively with standard therapies, resulting in poor prognoses for patients.
- A multicenter study analyzed the outcomes of adult patients who underwent allogeneic hematopoietic cell transplantation (HCT) in their first complete remission (CR1) for Ph-like ALL, comparing results to those of Philadelphia chromosome positive ALL (Ph-pos) and other B-cell Philadelphia negative ALL (Ph-neg).
- The findings indicated that patients with Ph-like ALL had outcomes similar to Ph-neg ALL after HCT, while Ph-pos ALL patients had significantly better survival rates, suggesting that effective second-line therapies in conjunction with HCT
Article Synopsis
- The Minnesota acute graft versus host disease (AGVHD) risk score helps categorize newly-diagnosed patients into standard-risk (SR) and high-risk (HR) groups, with about 85% falling into the SR category.
- A study analyzing 416 patients revealed that those with isolated upper gastrointestinal AGVHD had better recovery rates and lower one-year non-relapse mortality compared to those with lower gastrointestinal AGVHD.
- Factors such as age, lower GI involvement, and HCT-CI score were significant predictors of one-year non-relapse mortality, indicating the need for tailored risk stratification in clinical trials.